Publication:
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

dc.contributor.coauthorSimsek, Eda Tanrikulu
dc.contributor.coauthorEskazan, Ahmet Emre
dc.contributor.coauthorCengiz, Mahir
dc.contributor.coauthorAr, Muhlis Cem
dc.contributor.coauthorEkizoglu, Seda
dc.contributor.coauthorSalihoglu, Ayse
dc.contributor.coauthorGulturk, Emine
dc.contributor.coauthorElverdi, Tugrul
dc.contributor.coauthorAydin, Seniz Ongoren
dc.contributor.coauthorDemiroz, Ahu Senem
dc.contributor.coauthorBuyru, Ayse Nur
dc.contributor.coauthorBaslar, Zafer
dc.contributor.coauthorOzbek, Ugur
dc.contributor.coauthorAydin, Yildiz
dc.contributor.coauthorTuzuner, Nukhet
dc.contributor.coauthorSoysal, Teoman
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorFerhanoğlu, Ahmet Burhan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:59:47Z
dc.date.issued2016
dc.description.abstractAims Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy. Methods The study cohort consisted of 135 patients with CML who were exposed to imatinib. The grades of MF pre and post imatinib together with cytogenetic and molecular responses were evaluated. Results Severe MF (grade II-III) was observed in 44 (33%) patients prior to imatinib therapy, and in 8 (8%) after 12months of imatinib treatment (p=0.001). The complete cytogenetic response (CCyR) rates at 12months did not differ according to the pre-imatinib MF grades, and CCyR rates in patients with grades 0, I, II and III MF were 36/47 (76.5%), 26/33 (78.7%), 12/23 (52.1%) and 7/10 (70%), respectively (p=0.127). There was no significant difference between patients with or without CCyR at 12months of imatinib regarding grades of MF (p=0.785). The distribution of the major molecular response rates at 18months according to pre-treatment grades of MF were determined as grade 0 in 38/45 (84.4%), grade I in 21/28 (75%), grade II in 14/21 (66.6%) and grade III in 7/10 (70%) (p=0.112). There was no significant difference in overall survival rates between initial MF mild (grade 0-I) and severe (grade II-III) groups (p=0.278). Conclusions According to our findings, MF regresses with imatinib therapy over time, and the MF grades at diagnosis do not have a negative impact on the responses to imatinib treatment. Therefore, the adverse prognostic impact of the MF among patients with CML seems to disappear in the era of the TKIs.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue9
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipScientific Research Projects Coordination Unit of Istanbul University [3390] Scientific Research Projects Coordination Unit of Istanbul University (Project Number 3390).
dc.description.volume69
dc.identifier.doi10.1136/jclinpath-2015-203320
dc.identifier.eissn1472-4146
dc.identifier.issn0021-9746
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-84962184441
dc.identifier.urihttps://doi.org/10.1136/jclinpath-2015-203320
dc.identifier.urihttps://hdl.handle.net/20.500.14288/15684
dc.identifier.wos384323700012
dc.keywordsCml
dc.keywordsMyelofibros
dc.keywordsHematopathology chronic myelogenous leukemia
dc.keywordsKinase inhibitor Sti571
dc.keywordsChronic-phase
dc.keywordsRelevance
dc.keywordsTherapy
dc.keywordsRecommendations
dc.keywordsDiagnosis
dc.language.isoeng
dc.publisherBmj Publishing Group
dc.relation.ispartofJournal of Clinical Pathology
dc.subjectPathology
dc.titleImatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorFerhanoğlu, Ahmet Burhan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files